The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis

C Estes, 2018, Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030, J Hepatol, 69, 896, 10.1016/j.jhep.2018.05.036

R Loomba, 2013, The global NAFLD epidemic, Nat Rev Gastroenterol Hepatol, 10, 686, 10.1038/nrgastro.2013.171

Z Younossi, 2019, Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Hepatology, 69, 2672, 10.1002/hep.30251

E M Brunt, 1999, Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions, Am J Gastroenterol, 94, 2467, 10.1111/j.1572-0241.1999.01377.x

R S O'Shea, 2010, Alcoholic liver disease, Hepatology, 51, 307, 10.1002/hep.23258

M M Yeh, 2014, Pathological features of fatty liver disease, Gastroenterology, 147, 754, 10.1053/j.gastro.2014.07.056

P S Dulai, 2017, Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis, Hepatology, 65, 1557, 10.1002/hep.29085

H Perazzo, 2017, The therapeutic landscape of non-alcoholic steatohepatitis, Liver Int, 37, 634, 10.1111/liv.13270

G Lassailly, 2016, Perspectives on treatment for nonalcoholic steatohepatitis, Gastroenterology, 150, 1835, 10.1053/j.gastro.2016.03.004

E Vilar-Gomez, 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367.e5, 10.1053/j.gastro.2015.04.005

G Cholankeril, 2018, Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States, Clin Gastroenterol Hepatol, 16, 1356, 10.1016/j.cgh.2017.11.045

B Gao, 2019, Inflammatory pathways in alcoholic steatohepatitis, J Hepatol, 70, 249, 10.1016/j.jhep.2018.10.023

M Arrese, 2016, Innate immunity and inflammation in NAFLD/NASH, Dig Dis Sci, 61, 1294, 10.1007/s10620-016-4049-x

J C Cohen, 2011, Human fatty liver disease: old questions and new insights, Science, 332, 1519, 10.1126/science.1204265

T Próchnicki, 2016, Recent insights into the molecular mechanisms of the NLRP3 inflammasome activation, F1000 Res, 5, 5, 10.12688/f1000research.8614.1

G Guarda, 2011, Differential expression of NLRP3 among hematopoietic cells, J Immunol, 186, 2529, 10.4049/jimmunol.1002720

A S Yazdi, 2010, The role of the inflammasome in nonmyeloid cells, J Clin Immunol, 30, 623, 10.1007/s10875-010-9437-y

L M Booshehri, 2019, CAPS and NLRP3, J Clin Immunol, 39, 277, 10.1007/s10875-019-00638-z

K Schroder, 2010, The inflammasomes, Cell, 140, 821, 10.1016/j.cell.2010.01.040

X Liu, 2016, Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores, Nature, 535, 153, 10.1038/nature18629

N Kayagaki, 2015, Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling, Nature, 526, 666, 10.1038/nature15541

J Shi, 2015, Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death, Nature, 526, 660, 10.1038/nature15514

T Csak, 2011, Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells, Hepatology, 54, 133, 10.1002/hep.24341

A Wree, 2014, NLRP3 inflammasome activation is required for fibrosis development in NAFLD, J Mol Med (Berl), 92, 1069, 10.1007/s00109-014-1170-1

A R Mridha, 2017, NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice, J Hepatol, 66, 1037, 10.1016/j.jhep.2017.01.022

C Blasetti Fantauzzi, 2017, Deficiency of the purinergic receptor 2X7 attenuates nonalcoholic steatohepatitis induced by high-fat diet: possible role of the NLRP3 inflammasome, Oxid Med Cell Longev, 2017, 8962458, 10.1155/2017/8962458

L J Dixon, 2012, Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis, Lab Invest, 92, 713, 10.1038/labinvest.2012.45

L J Dixon, 2013, Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis, PLoS One, 8, e56100, 10.1371/journal.pone.0056100

J Henao-Mejia, 2012, Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity, Nature, 482, 179, 10.1038/nature10809

C A Rivera, 2007, Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis, J Hepatol, 47, 571, 10.1016/j.jhep.2007.04.019

P Brun, 2007, Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis, Am J Physiol Gastrointest Liver Physiol, 292, G518, 10.1152/ajpgi.00024.2006

K Nakanishi, 2019, Exogenous administration of low-dose lipopolysaccharide potentiates liver fibrosis in a choline-deficient l-amino-acid-defined diet-induced murine steatohepatitis model, Int J Mol Sci, 20, 2724, 10.3390/ijms20112724

B Xu, 2018, Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice, J Hepatol, 68, 773, 10.1016/j.jhep.2017.11.040

S Lang, 2020, Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis, Hepatology, 71, 522, 10.1002/hep.30832

S K Sarin, 2019, Microbiome as a therapeutic target in alcohol-related liver disease, J Hepatol, 70, 260, 10.1016/j.jhep.2018.10.019

G Szabo, 2015, Gut-liver axis in alcoholic liver disease, Gastroenterology, 148, 30, 10.1053/j.gastro.2014.10.042

Y Duan, 2019, Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease, Nature, 575, 505, 10.1038/s41586-019-1742-x

J Petrasek, 2012, IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice, J Clin Invest, 122, 3476, 10.1172/JCI60777

J Petrasek, 2015, Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells in alcoholic liver disease, J Leukoc Biol, 98, 249, 10.1189/jlb.3AB1214-590R

A Iracheta-Vellve, 2015, Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice, J Hepatol, 63, 1147, 10.1016/j.jhep.2015.06.013

M J Heo, 2019, Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression, Gut, 68, 708, 10.1136/gutjnl-2017-315123

E Khanova, 2018, Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients, Hepatology, 67, 1737, 10.1002/hep.29645

M V Machado, 2015, Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease, PLoS One, 10, e0127991, 10.1371/journal.pone.0127991

J Pihlajamäki, 2012, Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans, J Hepatol, 56, 663, 10.1016/j.jhep.2011.10.005

K He, 2017, Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development, Oncotarget, 8, 37657, 10.18632/oncotarget.17489

L Zhu, 2013, Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH, Hepatology, 57, 601, 10.1002/hep.26093

V W-S Wong, 2013, Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study, PLoS One, 8, e62885, 10.1371/journal.pone.0062885

J Boursier, 2016, The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota, Hepatology, 63, 764, 10.1002/hep.28356

R W Grant, 2013, Mechanisms of disease: inflammasome activation and the development of type 2 diabetes, Front Immunol, 4, 50, 10.3389/fimmu.2013.00050

G H Goossens, 2012, Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans, Mol Immunol, 50, 142, 10.1016/j.molimm.2012.01.005

H-M Lee, 2013, Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes, Diabetes, 62, 194, 10.2337/db12-0420

K Ohashi, 2018, Alcoholic liver disease: a current molecular and clinical perspective, Liver Res, 2, 161, 10.1016/j.livres.2018.11.002

T R Morgan, 2004, Alcohol and hepatocellular carcinoma, Gastroenterology, 127, S87, 10.1053/j.gastro.2004.09.020

K Nurmi, 2013, Ethanol inhibits activation of NLRP3 and AIM2 inflammasomes in human macrophages--a novel anti-inflammatory action of alcohol, PLoS One, 8, e78537, 10.1371/journal.pone.0078537

L R Hoyt, 2016, Ethanol and other short-chain alcohols inhibit NLRP3 inflammasome activation through protein tyrosine phosphatase stimulation, J Immunol, 197, 1322, 10.4049/jimmunol.1600406

L R Hoyt, 2017, Mitochondrial ROS induced by chronic ethanol exposure promote hyper-activation of the NLRP3 inflammasome, Redox Biol, 12, 883, 10.1016/j.redox.2017.04.020

B Le Daré, 2019, Ethanol upregulates the P2 × 7 purinergic receptor in human macrophages, Fundam Clin Pharmacol, 33, 63, 10.1111/fcp.12433

C S Voican, 2015, Alcohol withdrawal alleviates adipose tissue inflammation in patients with alcoholic liver disease, Liver Int, 35, 967, 10.1111/liv.12575

Y Peng, 2014, The inflammasome in alcoholic hepatitis: its relationship with Mallory-Denk body formation, Exp Mol Pathol, 97, 305, 10.1016/j.yexmp.2014.08.006

S Leclercq, 2014, Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity, Proc Natl Acad Sci U S A, 111, E4485, 10.1073/pnas.1415174111

E A Mutlu, 2012, Colonic microbiome is altered in alcoholism, Am J Physiol Gastrointest Liver Physiol, 302, G966, 10.1152/ajpgi.00380.2011

G Szabo, 2018, IL-1 receptor antagonist in combination with pentoxifylline and zinc for severe alcoholic hepatitis: a multicenter randomized double-bind placebo-controlled clinical trial, Hepatology, 68, 1444A, 10.1002/hep.30353

M G Thomas, 2019, Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial, BMJ Open, 9, e023765, 10.1136/bmjopen-2018-023765

S B Cohen, 2011, A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee, Arthritis Res Ther, 13, R125, 10.1186/ar3430

M R Thursz, 2015, Prednisolone or pentoxifylline for alcoholic hepatitis, N Engl J Med, 372, 1619, 10.1056/NEJMoa1412278

S Naveau, 2004, A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis, Hepatology, 39, 1390, 10.1002/hep.20206

C O Zein, 2011, Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial, Hepatology, 54, 1610, 10.1002/hep.24544

M C Morrison, 2016, Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice, Int J Obes, 40, 1416, 10.1038/ijo.2016.74

J H Stack, 2005, IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients, J Immunol, 175, 2630, 10.4049/jimmunol.175.4.2630

W Wannamaker, 2007, (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18, J Pharmacol Exp Ther, 321, 509, 10.1124/jpet.106.111344

D Cabrera, 2017, Andrographolide ameliorates inflammation and fibrogenesis and attenuates inflammasome activation in experimental non-alcoholic steatohepatitis, Sci Rep, 7, 3491, 10.1038/s41598-017-03675-z

R C Coll, 2015, A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases, Nat Med, 21, 248, 10.1038/nm.3806

C Juliana, 2010, Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome, J Biol Chem, 285, 9792, 10.1074/jbc.M109.082305

H Honda, 2014, Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation, J Leukoc Biol, 96, 1087, 10.1189/jlb.3A0114-005RR

C J Calvente, 2019, Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223, J Clin Invest, 130, 4091, 10.1172/JCI122258

C Jimenez Calvente, 2019, MicroRNA 223 3p negatively regulates the NLRP3 inflammasome in acute and chronic liver injury, Mol Ther, 10.1016/j.ymthe.2019.09.013

J K Rathkey, 2018, Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis, Sci Immunol, 3, eaat2738, 10.1126/sciimmunol.aat2738